These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 12631626)

  • 21. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
    Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
    Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW; Lau KW; Tam PC; Shiu SY
    Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.
    Mellinghoff IK; Tran C; Sawyers CL
    Cancer Res; 2002 Sep; 62(18):5254-9. PubMed ID: 12234993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha.
    Miyake K; Tsuchida K; Sugino H; Imura S; Morine Y; Fujii M; Shimada M
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):113-26. PubMed ID: 16699793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice.
    Park YW; Younes MN; Jasser SA; Yigitbasi OG; Zhou G; Bucana CD; Bekele BN; Myers JN
    Clin Cancer Res; 2005 Mar; 11(5):1963-73. PubMed ID: 15756022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
    Karashima T; Sweeney P; Slaton JW; Kim SJ; Kedar D; Izawa JI; Fan Z; Pettaway C; Hicklin DJ; Shuin T; Dinney CP
    Clin Cancer Res; 2002 May; 8(5):1253-64. PubMed ID: 12006546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells.
    Radinsky R; Risin S; Fan D; Dong Z; Bielenberg D; Bucana CD; Fidler IJ
    Clin Cancer Res; 1995 Jan; 1(1):19-31. PubMed ID: 9815883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice.
    Kedar D; Baker CH; Killion JJ; Dinney CP; Fidler IJ
    Clin Cancer Res; 2002 Nov; 8(11):3592-600. PubMed ID: 12429651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells.
    Levine L; Lucci JA; Pazdrak B; Cheng JZ; Guo YS; Townsend CM; Hellmich MR
    Cancer Res; 2003 Jul; 63(13):3495-502. PubMed ID: 12839933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
    Kim SJ; Uehara H; Yazici S; Busby JE; Nakamura T; He J; Maya M; Logothetis C; Mathew P; Wang X; Do KA; Fan D; Fidler IJ
    J Natl Cancer Inst; 2006 Jun; 98(11):783-93. PubMed ID: 16757703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
    Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
    Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein.
    Dorai T; Gehani N; Katz A
    Mol Urol; 2000; 4(1):1-6. PubMed ID: 10851300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.
    Inoue K; Slaton JW; Eve BY; Kim SJ; Perrotte P; Balbay MD; Yano S; Bar-Eli M; Radinsky R; Pettaway CA; Dinney CP
    Clin Cancer Res; 2000 May; 6(5):2104-19. PubMed ID: 10815938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor.
    Harper ME; Goddard L; Glynne-Jones E; Assender J; Dutkowski CM; Barrow D; Dewhurst OL; Wakeling AE; Nicholson RI
    Prostate; 2002 Jun; 52(1):59-68. PubMed ID: 11992620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
    Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.